Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial

Abstract Aims In people at risk of heart failure (HF) enrolled in the Heart ‘OMics’ in AGEing (HOMAGE) trial, spironolactone reduced circulating markers of collagen synthesis, natriuretic peptides, and blood pressure and improved cardiac structure and function. In the present report, we explored fac...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Luca Monzo, João Pedro Ferreira, John G.F. Cleland, Pierpaolo Pellicori, Beatrice Mariottoni, Job A.J. Verdonschot, Mark R. Hazebroek, Tim J. Collier, Joe J. Cuthbert, Burkert Pieske, Frank Edelmann, Johannes Petutschnigg, Javed Khan, Fozia Z. Ahmed, Nicolas Girerd, Erwan Bozec, Javier Díez, Arantxa González, Andrew L. Clark, Franco Cosmi, Jan A. Staessen, Stephane Heymans, Patrick Rossignol, Faiez Zannad
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Oxford University Press 2022-12-01
Sarja:	ESC Heart Failure
Aiheet:	Hyperkalaemia Hypokalaemia Steroidal mineralocorticoid receptor antagonist Heart failure prevention
Linkit:	https://doi.org/10.1002/ehf2.14086
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!